Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HYCAMTIN · 1 trial · 1 indication
Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.
| Arm | Type | Description |
|---|---|---|
| topotecan plus radiation | EXPERIMENTAL | topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy. |
| Whole brain radiation | ACTIVE_COMPARATOR | Whole brain radiation 3 Gy/day for 10 days |
| Name | Type | Description |
|---|---|---|
| HYCAMTIN, oral capsules | DRUG | topotecan oral capsules 1.1 mg/m2 |
| Radiation | RADIATION | Whole brain radiation |
Inclusion criteria: * At least one measurable cancerous lesion in the brain from primary non-small cell lung cancer (NSCLC) * Must have received previous chemotherapy * Must be 18 years of age of greater * Must be Easter Cooperative Oncology Group (ECOG) Performance Status 0, 1, 2 * At least 2 week...
HYCAMTIN is a small molecule being studied for the treatment of Non-Small Cell Lung Cancer, specifically for brain metastases resulting from this cancer. It is an investigational drug in Phase 3 clinical development, and it is not yet approved for this use.
HYCAMTIN is a small molecule, but its specific molecular target is not disclosed in the available information. It is being investigated for its potential role in treating brain metastases from Non-Small Cell Lung Cancer.
HYCAMTIN is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
HYCAMTIN is in Phase 3 clinical development for Non-Small Cell Lung Cancer. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to determine its safety and effectiveness.
HYCAMTIN has one completed Phase 3 clinical trial, identified as NCT00390806. This trial studied oral HYCAMTIN plus whole brain radiation therapy in the treatment of brain metastases resulting from Non-Small Cell Lung Cancer, enrolling 472 participants.
HYCAMTIN is a brand name for the drug topotecan, which is a chemotherapy agent. In the context of the available information, HYCAMTIN refers to this drug, and it is being investigated for use in Non-Small Cell Lung Cancer with brain metastases.